^
Association details:
Biomarker:KRAS G12A
Cancer:Chronic Lymphocytic Leukemia
Drug:GT19077 (MYC inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Abstract LB-111: GT19077, a c-Myc/Max protein-protein interaction (PPI) small molecule inhibitor, selectively targets c-Myc-additive B-cell and myeloid malignancies

Published date:
06/23/2020
Excerpt:
Profiling on the proliferation of a selected 14 hematologic malignant cell panel with c-Myc overexpression, GT19077 selectively inhibited the proliferation of all seven B-cell malignant cell lines tested, which include three carrying Myc-IGH translocations and two expressing Kras G12A mutations, with IC50s as low as 160 nM.
DOI:
10.1158/1538-7445.AM2020-LB-111